12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fycompa perampanel regulatory update

Germany's Federal Joint Committee (G-BA) issued final benefit assessments for epilepsy drug Fycompa perampanel from Eisai saying that Fycompa has no additional benefit over comparators to treat partial onset seizures, with or without secondarily generalized seizures, in patients...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >